

# Carbamazepine-Induced Toxic Effects and HLA-B\*1502

New England Journal of Medicine

364, 1126-1133

DOI: [10.1056/nejmoa1009717](https://doi.org/10.1056/nejmoa1009717)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Personalizing carbamazepine therapy. <i>Genome Medicine</i> , 2011, 3, 28.	3.6	1
2	Promises and partnership: FDA's Critical Path Initiative and its intersection with pharmacology: an ASPET 2011 annual meeting symposium. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 827-837.	1.0	3
3	Carbamazepine ADRs reduced with genetic screening. <i>Reactions Weekly</i> , 2011, &NA;, 1.	0.0	0
5	Biomarkers in epilepsy: introduction. <i>Biomarkers in Medicine</i> , 2011, 5, 537-544.	0.6	65
6	Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1266-1276.e11.	1.5	237
7	Drug-induced epidermal necrolysis: Important new piece to end the puzzle. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1277-1278.	1.5	20
8	Personalizing medicine with clinical pharmacogenetics. <i>Genetics in Medicine</i> , 2011, 13, 987-995.	1.1	173
9	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. <i>New England Journal of Medicine</i> , 2011, 364, 1134-1143.	13.9	815
10	Adjunctive lacosamide in clinical practice: Sodium blockade with a difference?. <i>Epilepsy and Behavior</i> , 2011, 22, 499-504.	0.9	31
11	The patterns of outpatient off-label carbamazepine use and the potential impact of regulatory labelling process in Taiwan. <i>Journal of Pharmaceutical Health Services Research</i> , 2011, 2, 165-173.	0.3	1
13	Carbamazepine Hypersensitivity: Progress toward Predicting the Unpredictable. <i>Epilepsy Currents</i> , 2011, 11, 189-191.	0.4	10
14	wo papers on carbamazepine-induced hypersensitivity and its relationship to HLA status. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2011, 41, 221-222.	0.2	0
15	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 906-910.	0.7	77
16	Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory Guidance. <i>Annals of Internal Medicine</i> , 2011, 154, 842.	2.0	9
17	Education of a Child Neurologist: Developmental Neuroscience Relevant to Child Neurology. <i>Seminars in Pediatric Neurology</i> , 2011, 18, 133-138.	1.0	5
18	Rechercher lâ€™allÃ©le HLA-A*3101 avant de prescrire de la carbamazÃ©pine ?. <i>Option/Bio</i> , 2011, 22, 5.	0.0	0
19	Pharmacogenomics and epilepsy: the road ahead. <i>Pharmacogenomics</i> , 2011, 12, 1429-1447.	0.6	31
20	Cardiovascular Pharmacogenomics. <i>Circulation Research</i> , 2011, 109, 807-820.	2.0	71

#	ARTICLE	IF	CITATIONS
21	Genetische Untersuchungen bei Epilepsien. Zeitschrift Fur Epileptologie, 2011, 24, 85-86.	0.2	0
24	Pharmacogenomics in neurology: Current state and future steps. Annals of Neurology, 2011, 70, 684-697.	2.8	33
25	Genetics of Epilepsy. Seminars in Neurology, 2011, 31, 506-518.	0.5	39
26	Genetics and Variable Drug Response. JAMA - Journal of the American Medical Association, 2011, 306, 306-7.	3.8	50
28	HLA alleles linked to carbamazepine hypersensitivity. Nature Reviews Neurology, 2011, 7, 365-366.	4.9	5
29	Genomics and Drug Response. New England Journal of Medicine, 2011, 364, 1144-1153.	13.9	552
30	HLA-B*1502 Screening and Toxic Effects of Carbamazepine. New England Journal of Medicine, 2011, 365, 672-673.	13.9	23
31	Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology, 2012, 79, 1259-1267.	1.5	113
32	T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction. Expert Review of Clinical Immunology, 2012, 8, 467-477.	1.3	15
33	HLA-B*1502 screening in carbamazepine and lamotrigine candidates of Asian background. Australian and New Zealand Journal of Psychiatry, 2012, 46, 1106-1107.	1.3	4
34	Genetics and the Potential for Predictive Tests in Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 18-31.	1.7	42
35	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Chemical Immunology and Allergy, 2012, 97, 149-166.	1.7	67
37	Risk models for revascularization—the search continues. Nature Reviews Cardiology, 2012, 9, 316-318.	6.1	4
38	Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Review of Neurotherapeutics, 2012, 12, 343-352.	1.4	39
39	Investigative safety science as a competitive advantage for Pharma. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1071-1082.	1.5	24
40	HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 2012, 13, 1285-1306.	0.6	161
41	Insights into epilepsy treatments and biomarkers. Nature Reviews Neurology, 2012, 8, 70-71.	4.9	6
42	Opportunities and Challenges for Genome Sequencing in the Clinic. Advances in Protein Chemistry and Structural Biology, 2012, 89, 65-83.	1.0	9

#	ARTICLE	IF	CITATIONS
43	A Recent Update of Pharmacogenomics in Drug-induced Severe Skin Reactions. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 132-141.	1.1	36
44	Development of a Rapid and Inexpensive Assay for Detecting a Surrogate Genetic Polymorphism of HLA-B*58:01: A Partially Predictive but Useful Biomarker for Allopurinol-related Stevens-Johnson Syndrome/toxic Epidermal Necrolysis in Japanese. <i>Drug Metabolism and Pharmacokinetics</i> , 2012, 27, 447-450.	1.1	27
45	HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. <i>Yearbook of Pediatrics</i> , 2012, 2012, 558-559.	0.2	0
46	Pharmacogenomics in clinical practice and drug development. <i>Nature Biotechnology</i> , 2012, 30, 1117-1124.	9.4	91
47	Will SNPs be useful predictors of normal tissue radiosensitivity in the future?. <i>Radiotherapy and Oncology</i> , 2012, 105, 283-288.	0.3	20
48	A unique drug-injury relief system in Taiwan: comparing drug-injury compensation in different countries. <i>Journal of Pharmaceutical Health Services Research</i> , 2012, 3, 3-9.	0.3	6
49	Antiepileptic Drugs 2012: Recent Advances and Trends. <i>Mayo Clinic Proceedings</i> , 2012, 87, 879-889.	1.4	53
50	Use of carbamazepine and lamotrigine in a Taiwanese diabetic patient with bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 538-539.	1.0	3
51	Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine. <i>Inflammopharmacology</i> , 2012, 20, 245-250.	1.9	1
52	High points and hurdles in the translation of genomics. <i>Translational Research</i> , 2012, 159, 61-63.	2.2	1
53	Stiripentol: An example of antiepileptic drug development in childhood epilepsies. <i>European Journal of Paediatric Neurology</i> , 2012, 16, S13-S17.	0.7	20
55	TNF- $\alpha$ genetic polymorphism $\gamma$ 308G/A and antituberculosis drug-induced hepatitis. <i>Liver International</i> , 2012, 32, 809-814.	1.9	29
56	Ready When You Are: Easing Into Preemptive Pharmacogenetics. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 412-414.	2.3	11
57	Dialogues in Dermatology: Highlights from 2011. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 153-156.	0.6	0
58	Personalized medicine in multiple sclerosis: hope or reality?. <i>BMC Medicine</i> , 2012, 10, 116.	2.3	54
59	HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 757-765.	2.3	137
60	Clinical Application of Pharmacogenomics. <i>Journal of Pharmacy Practice</i> , 2012, 25, 417-427.	0.5	54
61	Adverse effects of antiepileptic drugs. <i>Lancet Neurology</i> , The, 2012, 11, 792-802.	4.9	511

#	ARTICLE	IF	CITATIONS
62	Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1562-1569.e5.	1.5	262
63	Drug Reaction with Eosinophilia and Systemic Symptoms: an update on pathogenesis. <i>Current Opinion in Immunology</i> , 2012, 24, 730-735.	2.4	64
64	Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. <i>New Biotechnology</i> , 2012, 29, 757-768.	2.4	29
65	Genetic association studies in drug-induced liver injury. <i>Drug Metabolism Reviews</i> , 2012, 44, 116-126.	1.5	100
67	Pharmacogenomic Mechanisms of Drug Toxicity. , 2012, , 285-306.		0
68	A sÃndrome de Stevens-Johnson em pacientes neurocirÃrgicos. <i>Brazilian Neurosurgery</i> , 2012, 31, 231-236.	0.0	0
69	A rare but severe pulmonary side effect of cetuximab in two patients. <i>BMJ Case Reports</i> , 2012, 2012, bcr0320125973-bcr0320125973.	0.2	17
70	Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the &#8220;Know-Do&#8221; Gap Across the Personalized Medicine Innovation Ecosystem. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2012, 10, 277-287.	0.2	5
71	Looking back at genomic medicine in 2011. <i>Genome Medicine</i> , 2012, 4, 9.	3.6	10
72	Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 21-35.	4.2	100
73	Point-of-care genetic testingâ€”a new frontier explored. <i>Nature Reviews Cardiology</i> , 2012, 9, 315-316.	6.1	6
74	Opportunities for Cost Reduction of Medical Care: Part 3. <i>Journal of Community Health</i> , 2012, 37, 888-896.	1.9	7
75	Severe drug eruptions revisited. <i>Immunologic Research</i> , 2012, 53, 162-167.	1.3	1
76	The management of toxic epidermal necrolysis. <i>Australasian Journal of Dermatology</i> , 2012, 53, 165-171.	0.4	51
77	Pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. <i>British Journal of Dermatology</i> , 2012, 166, 7-11.	1.4	8
78	Response 1 to pharmacogenetic screening to prevent carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: a critical appraisal. <i>British Journal of Dermatology</i> , 2012, 166, 11-12.	1.4	1
79	<i>HLAâ€B*1502</i> Strongly Predicts Carbamazepineâ€Induced Stevensâ€Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain. <i>Pain Practice</i> , 2012, 12, 202-208.	0.9	93
80	HLA alleles and drug hypersensitivity reactions. <i>International Journal of Immunogenetics</i> , 2012, 39, 99-105.	0.8	32

#	ARTICLE	IF	CITATIONS
81	Prediction of Drug Response and Safety in Clinical Practice. <i>Journal of Medical Toxicology</i> , 2012, 8, 43-51.	0.8	30
82	Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 608-612.	1.0	42
83	Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1909-1916.	0.8	55
84	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 324-328.	2.3	237
85	Toxic epidermal necrolysis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 330-336.	1.1	43
86	Toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 187.e1-187.e16.	0.6	244
87	HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 142-149.	2.3	110
88	Economic evaluation of <scp>HLA</scp>â€B*15:02 screening for carbamazepineâ€induced severe adverse drug reactions in <scp>T</scp>hailand. <i>Epilepsia</i> , 2013, 54, 1628-1638.	2.6	73
89	Drug-induced arrhythmia: pharmacogenomic prescribing?. <i>European Heart Journal</i> , 2013, 34, 89-95.	1.0	72
90	Status report from â€double agent HLAâ€™™: Health and disease. <i>Molecular Immunology</i> , 2013, 55, 2-7.	1.0	15
91	Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 493-495.	1.5	12
92	Epidermal necrolysis (Stevensâ€™Johnson syndrome and toxic epidermal necrolysis): Historical considerations. <i>Dermatologica Sinica</i> , 2013, 31, 169-174.	0.2	10
93	Drugs for neuropathic pain. <i>BMJ, The</i> , 2013, 347, f7339-f7339.	3.0	91
94	Personalized medicine: myth or reality? The position of Russian clinical pharmacologists. <i>EPMA Journal</i> , 2013, 4, 13.	3.3	5
95	Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 58-66.	0.8	13
96	Pharmacogenetic tests: the need for a level playing field. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 3-4.	21.5	39
97	Omics and Drug Response. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 475-502.	4.2	130
98	Consequences of drug binding to immune receptors: Immune stimulation following pharmacological interaction with immune receptors (T-cell receptor for antigen or human leukocyte antigen) with altered peptide-human leukocyte antigen or peptide. <i>Dermatologica Sinica</i> , 2013, 31, 181-190.	0.2	13

#	ARTICLE	IF	CITATIONS
99	Epidemiology of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. Dermatologica Sinica, 2013, 31, 217-220.	0.2	12
100	Translation of genetic findings to clinical practice in juvenile myoclonic epilepsy. Epilepsy and Behavior, 2013, 26, 241-246.	0.9	6
101	Symptoms of atopic dermatitis are influenced by outdoor air pollution. Journal of Allergy and Clinical Immunology, 2013, 132, 495-498.e1.	1.5	157
102	Developing a data mining approach to investigate association between physician prescription and patient outcome â€“ A study on re-hospitalization in Stevensâ€“Johnson Syndrome. Computer Methods and Programs in Biomedicine, 2013, 112, 84-91.	2.6	17
104	Pharmacogenetics of Allopurinolâ€“Making an Old Drug Safer. Journal of Clinical Pharmacology, 2013, 53, 675-679.	1.0	12
105	T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms. Chemical Research in Toxicology, 2013, 26, 759-766.	1.7	51
106	Pharmacogenetics and Pharmacogenomics. , 2013, , 362-371.		0
107	Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. Journal of Human Genetics, 2013, 58, 317-326.	1.1	68

108

#	ARTICLE	IF	CITATIONS
120	Idiosyncratic Adverse Drug Reactions: Current Concepts. <i>Pharmacological Reviews</i> , 2013, 65, 779-808.	7.1	253
121	<i>HLA-B*58:01</i> is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population. <i>British Journal of Dermatology</i> , 2013, 169, 660-665.	1.4	107
122	A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 528-532.	0.7	14
123	Predicting the Cost and Pace of Pharmacogenomic Advances: An Evidence-Based Study. <i>Clinical Chemistry</i> , 2013, 59, 649-657.	1.5	15
126	Pharmacogenomics of severe cutaneous adverse reactions. <i>Pharmacogenomics</i> , 2013, 14, 595-598.	0.6	6
127	Pediatrician! Do You Know the Symptoms of DRESS Syndrome?. <i>Pediatric Emergency Care</i> , 2013, 29, 504-507.	0.5	11
129	Genetic testing for prevention of severe drug-induced skin rash. <i>The Cochrane Library</i> , 2013, , .	1.5	6
130	What Taiwan contributes to the world of allergy and clinical immunology?. <i>Asia Pacific Allergy</i> , 2013, 3, 209-214.	0.6	3
131	Multi-Indication Carbamazepine and the Risk of Severe Cutaneous Adverse Drug Reactions in Korean Elderly Patients: A Korean Health Insurance Data-Based Study. <i>PLoS ONE</i> , 2013, 8, e83849.	1.1	15
132	Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective. <i>Asia Pacific Allergy</i> , 2013, 3, 215-223.	0.6	37
133	Severe Cutaneous Adverse Reactions. , 0, , .		0
134	HLA and the Pharmacogenomics of Drug Hypersensitivity. , 2014, , 437-465.		5
135	Return of results in the genomic medicine projects of the eMERGE network. <i>Frontiers in Genetics</i> , 2014, 5, 50.	1.1	40
136	Association Between HLA Gene Polymorphism and Antiepileptic Drugs-Induced Cutaneous Adverse Reactions. , 0, , .		0
137	Regulatory T Cells in Severe Drug Eruptions. <i>Current Immunology Reviews</i> , 2014, 10, 41-50.	1.2	4
138	PGx/Biomarker Utilization for Regulatory Decision Making. , 2014, , 951-967.		1
139	Sporadic nocturnal frontal lobe epilepsy: A consecutive series of 8 cases. <i>Sleep Science</i> , 2014, 7, 170-177.	0.4	4
140	Pharmacogenomics and Stratified Medicine. , 2014, , 3-25.		21



#	ARTICLE	IF	CITATIONS
141	Cytotoxic Proteins and Therapeutic Targets in Severe Cutaneous Adverse Reactions. <i>Toxins</i> , 2014, 6, 194-210.	1.5	47
142	Genetic Basis of Drug-Induced Liver Injury: Present and Future. <i>Seminars in Liver Disease</i> , 2014, 34, 123-133.	1.8	101
143	Screening for 392 polymorphisms in 141 pharmacogenes. <i>Biomedical Reports</i> , 2014, 2, 463-476.	0.9	11
144	Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. <i>Neurology</i> , 2014, 83, 2077-2084.	1.5	97
145	Case Report of Two Cases of Fever, Rash, and Organ Involvement during the Treatment of Leprosy. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3130.	1.3	1
146	Implementing Clinical Pharmacogenetics: Point-of-Care and Pre-Emptive Testing. , 2014, , 921-930.		0
147	Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 341-358.	1.5	16
149	Lost in Translation (<sc>LiT</sc>): <sc>IUPHAR</sc> Review 6. <i>British Journal of Pharmacology</i> , 2014, 171, 2269-2290.	2.7	9
150	Letter: chronic <i>Salmonella typhi</i> carrier status and gall-bladder cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1439-1440.	1.9	1
151	Letter: chronic <i>Salmonella typhi</i> carrier status and gall-bladder cancer - authors'™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1440-1440.	1.9	0
152	Risk of oral antifungal agent-induced liver injury in <sc>T</sc>aiwanese. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 180-189.	1.1	51
153	The emerging era of pharmacogenomics: current successes, future potential, and challenges. <i>Clinical Genetics</i> , 2014, 86, 21-28.	1.0	68
156	HLA alleles and hypersensitivity to carbamazepine. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 94-112.	0.7	72
157	Pharmacogenetics at 50: Genomic Personalization Comes of Age. <i>Science Translational Medicine</i> , 2014, 6, 220ps1.	5.8	19
158	Genomic architecture of pharmacological efficacy and adverse events. <i>Pharmacogenomics</i> , 2014, 15, 2025-2048.	0.6	21
159	Implementation and utilization of genetic testing in personalized medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 227.	0.4	63
160	HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	58
161	Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: Strength and clinical correlations. <i>Journal of Dermatological Science</i> , 2014, 73, 101-109.	1.0	76

#	ARTICLE	IF	CITATIONS
162	Human Leukocyte Antigen Genotypes and Trial of Desensitization in Patients With Oxcarbazepine-Induced Skin Rash: A Pilot Study. <i>Pediatric Neurology</i> , 2014, 51, 207-214.	1.0	12
163	Genetic Biomarkers in Epilepsy. <i>Neurotherapeutics</i> , 2014, 11, 324-333.	2.1	26
164	Genotyping for Severe Drug Hypersensitivity. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 418.	2.4	35
165	Predicting HLA genotypes using unphased and flanking single-nucleotide polymorphisms in Han Chinese population. <i>BMC Genomics</i> , 2014, 15, 81.	1.2	12
166	International consensus on drug allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 420-437.	2.7	733
167	Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. <i>Epilepsia</i> , 2014, 55, 496-506.	2.6	173
168	Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 254-257.	2.3	56
169	Dermatologic Side Effects of Psychotropic Medications. <i>Psychosomatics</i> , 2014, 55, 1-20.	2.5	36
170	The hidden genetics of epilepsy—a clinically important new paradigm. <i>Nature Reviews Neurology</i> , 2014, 10, 283-292.	4.9	232
171	Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies. <i>Pharmacogenomics Journal</i> , 2014, 14, 1-5.	0.9	12
172	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2014, 53, 123-139.	1.6	186
173	Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity. <i>Public Health Genomics</i> , 2014, 17, 248-255.	0.6	18
174	Establishment of Cloning and Sequencing Method for High-Resolution HLA-B Genotype Assay. <i>Chinese Journal of Analytical Chemistry</i> , 2014, 42, 1574-1579.	0.9	6
175	HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. <i>Pharmacogenomics Journal</i> , 2014, 14, 281-288.	0.9	199
176	Molecular Diagnostics for Dermatology. , 2014, , .		2
177	Adjunctive lacosamide—5 Years™ clinical experience. <i>Epilepsy Research</i> , 2014, 108, 1385-1391.	0.8	31
178	Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation. <i>Journal of Medical Genetics</i> , 2014, 51, 83-89.	1.5	41
179	The Path to Personalized Cardiovascular Medicine. , 2014, , 837-871.		0

#	ARTICLE	IF	CITATIONS
180	The consequences of refractory epilepsy and its treatment. <i>Epilepsy and Behavior</i> , 2014, 37, 59-70.	0.9	482
181	Prospective Validation of <i>HLA-DRB1*07:01</i> Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury. <i>Journal of Clinical Oncology</i> , 2014, 32, 2296-2303.	0.8	69
182	New technologies in molecular genetics. <i>Progress in Brain Research</i> , 2014, 213, 253-278.	0.9	6
183	Personalized Pharmacogenomics: Predicting Efficacy and Adverse Drug Reactions. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 349-370.	2.5	128
184	Strontium ranelate related Stevens-Johnson syndrome: a case report. <i>Osteoporosis International</i> , 2014, 25, 1813-1816.	1.3	13
185	Carbamazepine-induced cutaneous reactions: A simple assay to identify patients carrying the HLA-A*31:01 allele. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 644-647.	0.6	7
186	Integrating pharmacogenetic information and clinical decision support into the electronic health record. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 522-528.	2.2	61
187	Drug-Induced Liver Injury. , 2014, , 467-477.		0
188	Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 442-445.	0.7	15
189	Simple and rapid detection of HLA-A*31:01 for prediction of carbamazepine-induced hypersensitivity using loop-mediated isothermal amplification method. <i>Journal of Dermatological Science</i> , 2014, 74, 88-92.	1.0	8
190	Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 21-33.	2.0	74
191	Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives. <i>Gastroenterology</i> , 2014, 146, 914-928.e1.	0.6	222
192	Drug Allergy Diagnosis. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 461-471.	0.7	11
198	Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 519-524.	0.8	28
200	The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 154-164.	0.6	0
201	HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1305-1316.	1.4	12
202	Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 684-692.	0.9	41
203	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1149-1159.	1.1	28

#	ARTICLE	IF	CITATIONS
204	Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. <i>European Journal of Neurology</i> , 2015, 22, 1459-1468.	1.7	37
205	Clinical utility of eslicarbazepine: current evidence. <i>Drug Design, Development and Therapy</i> , 2015, 9, 781.	2.0	36
206	HLA-DRB1 and HLA-DQB1 Are Associated with Adult-Onset Immunodeficiency with Acquired Anti-Interferon-Gamma Autoantibodies. <i>PLoS ONE</i> , 2015, 10, e0128481.	1.1	41
207	HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese. <i>Asia Pacific Allergy</i> , 2015, 5, 68-77.	0.6	89
208	HLA-allele associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 186-198.	0.7	26
209	An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing. <i>Genetics in Medicine</i> , 2015, 17, 807-814.	1.1	34
211	Success stories in genomic medicine from resource-limited countries. <i>Human Genomics</i> , 2015, 9, 11.	1.4	41
212	Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1087-1206.	1.3	600
213	The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 369-379.	1.5	16
214	Toward stratified treatments for bipolar disorders. <i>European Neuropsychopharmacology</i> , 2015, 25, 283-294.	0.3	18
215	HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity. <i>Frontiers in Genetics</i> , 2014, 5, 478.	1.1	31
216	Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups. <i>Pharmacogenomics</i> , 2015, 16, 817-824.	0.6	18
217	Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2015, 17, 29-31.	0.8	10
218	Genotypes at rs2844682 and rs3909184 have no clinical value in identifying HLA-B*15:02 carriers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1021-1023.	0.8	9
219	Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1183-1204.	1.6	102
220	Role of dermatology in pharmacogenomics: drug-induced skin injury. <i>Pharmacogenomics</i> , 2015, 16, 401-412.	0.6	9
221	Tag SNPs for HLA-B alleles that are associated with drug response and disease risk in the Chinese Han population. <i>Pharmacogenomics Journal</i> , 2015, 15, 467-472.	0.9	13
222	Systems Pharmacological Analysis of Drugs Inducing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Chemical Research in Toxicology</i> , 2015, 28, 927-934.	1.7	18

#	ARTICLE	IF	CITATIONS
223	Association between HLA-DRB1*0405, -DQB1*0401 and -DQA1*0303 alleles and lamotrigine-induced cutaneous adverse drug reactions. A pilot case-control study from Japan. <i>Journal of Affective Disorders</i> , 2015, 179, 47-50.	2.0	12
224	Pharmacogenomic testing and response to warfarin. <i>Lancet, The</i> , 2015, 385, 2231-2232.	6.3	13
225	Textbook of Personalized Medicine. , 2015, , .		27
226	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 205-221.	0.7	19
227	Seizures in oligodendroglial tumors. <i>CNS Oncology</i> , 2015, 4, 347-356.	1.2	25
228	Development of a simple genotyping method for the <i>HLA-A*31:01</i>-tagging SNP in Japanese. <i>Pharmacogenomics</i> , 2015, 16, 1689-1699.	0.6	9
229	Stevensâ€™Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 475-493.	3.3	151
230	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. <i>Applied in Vitro Toxicology</i> , 2015, 1, 175-186.	0.6	5
231	Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. <i>BMJ, The</i> , 2015, 351, h4848.	3.0	148
232	Understanding the comparative effectiveness of treatment in pediatric epilepsy. <i>Neurology</i> , 2015, 84, 2298-2299.	1.5	1
233	New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 236-244.	1.5	80
234	The pharmacogenomics of epilepsy. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1161-1170.	1.4	33
235	Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1992-1993.	0.8	2
236	Immunopharmacogenomics. , 2015, , .		3
237	Association of <i>HLA</i>-B*1502 allele with lamotrigineâ€™induced Stevensâ€™Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a metaâ€™analysis. <i>International Journal of Dermatology</i> , 2015, 54, 488-493.	0.5	40
238	Personalized medicine approaches in epilepsy. <i>Journal of Internal Medicine</i> , 2015, 277, 218-234.	2.7	71
239	A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. <i>Drug Discovery Today</i> , 2015, 20, 37-49.	3.2	40
240	Immunological response in Stevensâ€™Johnson syndrome and toxic epidermal necrolysis. <i>Journal of Dermatology</i> , 2015, 42, 42-48.	0.6	35

#	ARTICLE	IF	CITATIONS
241	The Promise of Psychiatric Pharmacogenomics. <i>Biological Psychiatry</i> , 2015, 77, 29-35.	0.7	49
242	Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 48, 165-175.	2.9	57
243	Pharmacogenomics in Asthma Therapy: Where Are We and Where Do We Go?. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 129-147.	4.2	32
244	Toxic epidermal necrolysis. <i>F1000Research</i> , 2016, 5, 951.	0.8	19
245	T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. <i>Asia Pacific Allergy</i> , 2016, 6, 77-89.	0.6	38
246	Therapeutic drug safety for Indigenous Australians: how do we close the gap?. <i>Medical Journal of Australia</i> , 2016, 204, 16-17.	0.8	9
247	Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1890.	1.8	39
248	Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. <i>PLoS ONE</i> , 2016, 11, e0165933.	1.1	89
249	Pharmacogenetics and Pharmacogenomics. , 2016, , 121-137.		5
250	Review of Toxic Epidermal Necrolysis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2135.	1.8	43
251	Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. <i>Allergy, Asthma and Immunology Research</i> , 2016, 8, 3.	1.1	52
252	Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms. <i>International Archives of Allergy and Immunology</i> , 2016, 171, 166-179.	0.9	119
253	Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. <i>Australasian Journal of Dermatology</i> , 2016, 57, e137-e138.	0.4	2
254	Is DRESS syndrome a single entity or within a spectrum of adverse reactions to drug?. <i>British Journal of Dermatology</i> , 2016, 175, 1142-1144.	1.4	4
255	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2016, 375, 2263-2271.	13.9	71
256	Tooth-brushing epilepsy: A case report and literature review. <i>Clinical Neurology and Neurosurgery</i> , 2016, 145, 46-51.	0.6	8
257	Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1364-1369.e2.	1.5	25
258	A study of HLA-B*15:02 in a Sri Lankan population: Implications for pharmacogenomic testing. <i>Human Immunology</i> , 2016, 77, 429-431.	1.2	4

#	ARTICLE	IF	CITATIONS
259	What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 351-354.	1.3	15
260	Validation of a novel real-time PCR assay for detection of HLA-B*15:02 allele for prevention of carbamazepine â€œ induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in individuals of Asian ancestry. <i>Human Immunology</i> , 2016, 77, 1140-1146.	1.2	11
261	Pharmacogenomics and adverse drug reactions: Primetime and not ready for primetime tests. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 943-955.	1.5	18
262	Classifying ADRs â€œ does dose matter?. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 10-12.	1.1	27
263	Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. <i>Pharmacogenomics</i> , 2016, 17, 1365-1378.	0.6	33
264	Psychiatric Pharmacogenomics: How Close Are We?. <i>Biological Psychiatry</i> , 2016, 80, e63-e65.	0.7	7
265	Genetic risk factors for antiepileptic drugâ€œinduced hypersensitivity reactions in Israeli populations. <i>Epilepsia</i> , 2016, 57, e205-e209.	2.6	9
266	Clinical and regulatory considerations in pharmacogenetic testing. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1999-2006.	0.5	6
267	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1636-1646.	1.1	67
268	The Application of Genomics in Diabetes: Barriers to Discovery and Implementation. <i>Diabetes Care</i> , 2016, 39, 1858-1869.	4.3	25
269	Pharmacogenetic Tests in Psychiatry. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 299-304.	0.7	30
270	<i>HLAâ€œB*38:02:01</i> predicts carbimazole/methimazoleâ€œinduced agranulocytosis. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 555-561.	2.3	56
271	Stevensâ€œJohnson syndrome and toxic epidermal necrolysis: early recognition and prompt management may reduce mortality. <i>Drugs and Therapy Perspectives</i> , 2016, 32, 238-243.	0.3	1
273	Severe cutaneous adverse drug reactions. <i>Journal of Dermatology</i> , 2016, 43, 758-766.	0.6	169
274	Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. <i>Pharmacogenomics Journal</i> , 2016, 16, 180-185.	0.9	51
275	Adverse cutaneous drug eruptions: current understanding. <i>Seminars in Immunopathology</i> , 2016, 38, 75-86.	2.8	112
276	Advances in the Pharmacogenomics of Adverse Drug Reactions. <i>Drug Safety</i> , 2016, 39, 15-27.	1.4	29
277	Pharmacogenomics for personalized pain medicine. <i>Acta Anaesthesiologica Taiwanica</i> , 2016, 54, 24-30.	1.0	23

#	ARTICLE	IF	CITATIONS
278	Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage. <i>AAPS Journal</i> , 2016, 18, 757-766.	2.2	14
279	En neurologie: anti-convulsivants (surtout accidents retardés), biothérapies de la SEP. <i>Revue Française D'allergologie</i> , 2016, 56, 129-130.	0.1	0
280	Making Precision Medicine Socially Precise. Take a Deep Breath. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 348-350.	2.5	43
281	Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. <i>Neurology</i> , 2016, 86, 1086-1094.	1.5	37
282	Reactive Metabolites: Current and Emerging Risk and Hazard Assessments. <i>Chemical Research in Toxicology</i> , 2016, 29, 505-533.	1.7	114
283	Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Biomolecular Structure and Dynamics</i> , 2016, 34, 1806-1817.	2.0	103
284	Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. <i>International Journal of Immunogenetics</i> , 2017, 44, 7-26.	0.8	10
285	Donors <i>CYP2D6</i> polymorphisms affect tacrolimus elimination in Chinese liver transplant patients. <i>Pharmacogenomics</i> , 2017, 18, 265-275.	0.6	9
286	Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 248-255.	0.9	16
287	Recent advances in epilepsy. <i>Journal of Neurology</i> , 2017, 264, 1811-1824.	1.8	157
288	Pharmacogenetics of hypersensitivity drug reactions. <i>Thérapie</i> , 2017, 72, 231-243.	0.6	9
289	Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview. <i>CNS Drugs</i> , 2017, 31, 135-147.	2.7	23
290	Recent advances in the understanding of severe cutaneous adverse reactions. <i>British Journal of Dermatology</i> , 2017, 177, 1234-1247.	1.4	27
291	Trends in culprit drugs and clinical entities in cutaneous adverse drug reactions: a retrospective study. <i>Cutaneous and Ocular Toxicology</i> , 2017, 36, 370-376.	0.5	9
292	The Molecular Revolution in Cutaneous Biology: Era of Molecular Diagnostics for Inherited Skin Diseases. <i>Journal of Investigative Dermatology</i> , 2017, 137, e83-e86.	0.3	9
293	HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. <i>Neurology</i> , 2017, 88, 2183-2191.	1.5	89
294	Severe cutaneous adverse reactions to drugs. <i>Lancet</i> , The, 2017, 390, 1996-2011.	6.3	293
295	Pharmacogenetics and Pharmacogenomics. , 2017, , 233-246.		2



#	ARTICLE	IF	CITATIONS
296	HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysis. <i>Scientific Reports</i> , 2017, 7, 45553.	1.6	46
297	Prediction and management of drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 701-704.	1.5	24
298	Risk and association of <i>HLA</i> with oxcarbazepine-induced cutaneous adverse reactions in Asians. <i>Neurology</i> , 2017, 88, 78-86.	1.5	117
299	Genomics-Guided Precise Anti-Epileptic Drug Development. <i>Neurochemical Research</i> , 2017, 42, 2084-2088.	1.6	9
300	Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2368-2379.	1.6	157
301	Association between the HLA-B alleles and carbamazepine-induced SJS/TEN: A meta-analysis. <i>Epilepsy Research</i> , 2017, 135, 19-28.	0.8	41
302	Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach. <i>Pharmacogenomics</i> , 2017, 18, 881-890.	0.6	15
303	Pharmacogenetics and Pharmacogenomics. , 2017, , 89-107.		3
304	Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries. <i>Pharmacogenomics</i> , 2017, 18, 891-910.	0.6	15
305	Autoantibodies of nonâ€inflammatory bullous pemphigoid hardly deplete type <sc>XVII</sc> collagen of keratinocytes. <i>Experimental Dermatology</i> , 2017, 26, 1171-1174.	1.4	12
306	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 587.	2.0	30
307	Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 86-97.	2.3	32
308	Epilepsy research in 2016: new treatment directions. <i>Lancet Neurology</i> , The, 2017, 16, 7-9.	4.9	3
309	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 341-358.	2.3	240
310	Genomics of Adverse Drug Reactions. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 100-109.	4.0	53
311	NadwraÅ¼liwoÅ na leki â€“ rekomendacje wobec praktyki. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2017, 4, 146-151.	0.0	0
312	HLA-associated drug hypersensitivity and the prediction of adverse drug reactions. <i>Pharmacogenomics</i> , 2017, 18, 1441-1457.	0.6	29
313	Pharmacogenetics: a general review on progress to date. <i>British Medical Bulletin</i> , 2017, 124, 1-15.	2.7	48

#	ARTICLE	IF	CITATIONS
314	Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype. <i>Pharmacogenomics</i> , 2017, 18, 1643-1648.	0.6	36
315	A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. <i>Journal of Dermatological Science</i> , 2017, 88, 320-329.	1.0	29
316	Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1057-1071.	0.9	31
317	A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01 and HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions. <i>Hla</i> , 2017, 90, 335-342.	0.4	15
319	Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy. <i>OMICS A Journal of Integrative Biology</i> , 2017, 21, 647-657.	1.0	29
320	The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen. <i>Pharmacogenomics</i> , 2017, 18, 1041-1045.	0.6	19
321	Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Clinics in Plastic Surgery</i> , 2017, 44, 583-595.	0.7	17
322	Facile and phase-defined determination of HLA alleles with morpholino-functionalized nanoparticle probes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 611-618.	1.7	2
323	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital. <i>World Journal of Pediatrics</i> , 2017, 13, 255-260.	0.8	23
324	Genomic Medicine in Developing Countries and Resource-Limited Environments. , 2017, , 459-467.		0
325	The HLA-A*31:01 allele: influence on carbamazepine treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 29-38.	0.4	31
326	Precision Medicine in Primary Health Care. , 2017, , 101-113.		0
327	New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology. <i>Frontiers in Medicine</i> , 2017, 4, 179.	1.2	39
328	HLA Association with Drug-Induced Adverse Reactions. <i>Journal of Immunology Research</i> , 2017, 2017, 1-10.	0.9	111
329	Genetic Contributions and Personalized Medicine. , 2018, , 3-16.		1
330	Avoidance of Severe Cutaneous Adverse Drug Events as a First Step in Precision Neurology. <i>JAMA Neurology</i> , 2018, 75, 793.	4.5	1
331	Precision Medicine in the Management of Drug Allergy. <i>Current Treatment Options in Allergy</i> , 2018, 5, 60-73.	0.9	0
332	Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: a meta-analysis. <i>Pharmacogenomics</i> , 2018, 19, 547-552.	0.6	11

#	ARTICLE	IF	CITATIONS
333	Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 787-794.	2.3	77
334	Clinical Pharmacogenetics Implementation Consortium Guideline for <i>HLA</i> Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 574-581.	2.3	211
335	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
336	Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1101-1106.	0.3	9
337	Epilepsy. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18024.	18.1	541
338	Advancing Predictive Hepatotoxicity at the Intersection of Experimental, <i>in Silico</i>, and Artificial Intelligence Technologies. <i>Chemical Research in Toxicology</i> , 2018, 31, 412-430.	1.7	31
339	Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. <i>JAMA Neurology</i> , 2018, 75, 842.	4.5	52
340	Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 297-314.	1.6	15
341	SNP-based HLA allele tagging, imputation and association with antiepileptic drug-induced cutaneous reactions in Hong Kong Han Chinese. <i>Pharmacogenomics Journal</i> , 2018, 18, 340-346.	0.9	10
342	External quality assessment for laboratory testing of <i><scp>HLA</scp>â€15:02</i> allele in relation to carbamazepine therapy. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	1
343	Pharmacogenomics in epilepsy. <i>Neuroscience Letters</i> , 2018, 667, 27-39.	1.0	109
344	Pediatric allergy and immunology in China. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 127-132.	1.1	29
345	Biomarkers of adverse drug reactions. <i>Experimental Biology and Medicine</i> , 2018, 243, 291-299.	1.1	25
346	Pharmacogenomics of Drug Allergy. , 2018, , 39-51.		0
347	HLAs: Key regulators of Tâ€cellâ€mediated drug hypersensitivity. <i>Hla</i> , 2018, 91, 3-16.	0.4	72
348	Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes. <i>Pharmacogenomics Journal</i> , 2018, 18, 480-486.	0.9	17
349	Association between HLA-Bâ€46:01 and cutaneous adverse drug reactions in Han Chinese. <i>Journal of Bio-X Research</i> , 2018, 1, 73-78.	0.3	1
350	Traumatic lumbar hernia: clinical features and management. <i>Annals of Surgical Treatment and Research</i> , 2018, 95, 340.	0.4	8

#	ARTICLE	IF	CITATIONS
352	Immunogenicity and Immune-Related Adverse Drug Reactions. , 2018, , 498-517.		0
353	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Advances in Molecular Pathology</i> , 2018, 1, 125-134.	0.2	5
354	Gender, genetics, and analgesia: understanding the differences in response to pain relief. <i>Journal of Pain Research</i> , 2018, Volume 11, 2729-2739.	0.8	41
355	Temporal trends and patterns in carbamazepine use, related severe cutaneous adverse reactions, and <sc>HLA</sc>∗15:02 screening: A nationwide study. <i>Epilepsia</i> , 2018, 59, 2325-2339.	2.6	24
356	Pharmacogenetic testing in oncology: a Brazilian perspective. <i>Clinics</i> , 2018, 73, e565s.	0.6	6
357	Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait. <i>PLoS ONE</i> , 2018, 13, e0203033.	1.1	47
358	Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations. <i>Pharmaceutical Research</i> , 2018, 35, 211.	1.7	3
359	The HLA-B∗15:02 polymorphism and Tegretol ∆ <sup>®</sup> -induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis. <i>Revue Neurologique</i> , 2018, 174, 278-291.	0.6	17
360	Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. <i>Journal of Hepatology</i> , 2018, 69, 948-957.	1.8	62
362	Allergy to chlorpromazine and valproic acid following carbamazepine hypersensitivity in a patient with an HLA-B∗4601 allele. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 1139-1142.	1.0	3
363	Vancomycin-Induced Stevens-Johnson Syndrome in a Boy Under 2∆%Years Old: An Early Diagnosis by Granulysin Rapid Test. <i>Frontiers in Pediatrics</i> , 2018, 6, 26.	0.9	9
364	Common variation near IRF6 is associated with IFN-∆ <sup>2</sup> -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , 2018, 50, 1081-1085.	9.4	32
365	Carbamazepine as a Possible Anthropogenic Marker in Water: Occurrences, Toxicological Effects, Regulations and Removal by Wastewater Treatment Technologies. <i>Water (Switzerland)</i> , 2018, 10, 107.	1.2	124
366	Association of HLA-B<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:msup><mml:mrow /><mml:mrow><mml:mo>∆ <sup>-</sup> </mml:mo></mml:mrow></mml:math>38:02 with Antithyroid Drug-Induced Agranulocytosis in Kinh Vietnamese Patients. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-5.	0.6	18
368	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Pharmacology</i> , 2018, 83, 155-190.	1.2	32
369	Analysis of HLA-B Allelic Variation and IFN-∆ <sup>3</sup> ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 219-227.e4.	2.0	36
370	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	4.2	42
371	Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort. <i>American Journal of Transplantation</i> , 2019, 19, 801-810.	2.6	26

#	ARTICLE	IF	CITATIONS
372	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 782-789.	1.2	12
373	Seizure specificities in patients with antibody-mediated autoimmune encephalitis. <i>Epilepsia</i> , 2019, 60, 1508-1525.	2.6	57
374	Developing pharmacogenetic screening methods for an emergent country: Vietnam. <i>World Allergy Organization Journal</i> , 2019, 12, 100037.	1.6	13
375	Ethnicity-Specific Drug Safety Data in European Medicines Agency Registration Dossiers, European Public Assessment Reports, and European and Singapore Drug Labels: Lost in Translation?. <i>Pharmaceutical Medicine</i> , 2019, 33, 407-416.	1.0	3
376	Knowledge and opinions among Canadian academic physicians regarding genetic screening to prevent severe cutaneous adverse drug reactions. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1401-1405.	0.6	3
377	Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice. <i>Pharmacogenomics</i> , 2019, 20, 971-982.	0.6	13
378	Phenytoin-associated necrotising lymphadenitis mimicking Kikuchi disease. <i>Pathology</i> , 2019, 51, 650-653.	0.3	2
379	Reactive, Point-of-Care, Preemptive, and Direct-to-Consumer Pharmacogenomics Testing. , 2019, , 369-384.		3
380	Economic Evaluation of Pharmacogenomic Testing. , 2019, , 385-394.		0
381	Genome-Wide Gene-Environment Interaction Analysis Using Set-Based Association Tests. <i>Frontiers in Genetics</i> , 2018, 9, 715.	1.1	18
382	Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea. <i>Yonsei Medical Journal</i> , 2019, 60, 208.	0.9	14
383	Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 65-77.	1.9	51
384	Pharmacogenomics as a Tool for Management of Drug Hypersensitivity Reactions. <i>Current Treatment Options in Allergy</i> , 2019, 6, 1-17.	0.9	1
385	HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?. <i>Frontiers in Neurology</i> , 2019, 10, 614.	1.1	3
386	Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States. <i>Epilepsia</i> , 2019, 60, 1472-1481.	2.6	21
387	Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene. <i>Biological Psychiatry</i> , 2019, 86, 523-535.	0.7	32
388	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. <i>Drug Safety</i> , 2019, 42, 973-992.	1.4	66
389	Precision medicine in Thailand. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2019, 181, 245-253.	0.7	14

#	ARTICLE	IF	CITATIONS
390	A Screening Test for HLA-B*15:02 in a Large United States Patient Cohort Identifies Broader Risk of Carbamazepine-Induced Adverse Events. <i>Frontiers in Pharmacology</i> , 2019, 10, 149.	1.6	20
391	Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. <i>JAMA Dermatology</i> , 2019, 155, 666.	2.0	52
392	The role of pharmacogenomics in adverse drug reactions. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 407-442.	1.3	71
393	Immune pathomechanism and classification of drug hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1457-1471.	2.7	131
394	Working together to deliver stratified medicine research effectively. <i>British Medical Bulletin</i> , 2019, 129, 107-116.	2.7	3
395	Bioinformatics and Drug Discovery. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	2
396	A Computational Platform and Guide for Acceleration of Novel Medicines and Personalized Medicine. <i>Methods in Molecular Biology</i> , 2019, 1939, 181-198.	0.4	1
397	Purification, Crystallization and Crystallographic Analysis of HLA-B*15:02 Complexed with an Endogenous Peptide. <i>Crystallography Reports</i> , 2019, 64, 1122-1125.	0.1	1
398	Genetic testing for prevention of severe drug-induced skin rash. <i>The Cochrane Library</i> , 2019, 7, CD010891.	1.5	7
399	How does race and ethnicity effect the precision treatment of asthma?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 337-356.	0.4	7
400	Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. , 2019, , .		6
401	Analyses of Adverse Drug Reactions—Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 356-363.	1.0	13
402	HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 599-601.	0.8	2
403	Efficacy of the HLA-B*58:01 Screening Test in Preventing Allopurinol-Induced Severe Cutaneous Adverse Reactions in Patients with Chronic Renal Insufficiency—A Prospective Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1271-1276.	2.0	25
404	Conference report: pharmacogenomics in special populations at WCP2018. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 467-475.	1.1	3
405	Prevention and Diagnosis of Severe T-Cell-Mediated Adverse Drug Reactions: Are We There Yet?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 228-230.	2.0	3
406	The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. <i>Journal of Immunotoxicology</i> , 2019, 16, 1-12.	0.9	20
409	HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions. <i>Pharmacogenomics Journal</i> , 2019, 19, 277-285.	0.9	5

#	ARTICLE	IF	CITATIONS
410	Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , 2019, 19, 286-294.	0.9	17
411	The Medication Risk of Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 112-120.	2.3	54
412	Stevensâ€“Johnson syndrome and toxic epidermal necrolysis â€“ retrospective review of cases in a high complexity hospital in Brazil. <i>International Journal of Dermatology</i> , 2020, 59, 191-196.	0.5	6
413	<i>HLA*24:02</i> is associated with metronidazoleâ€“induced cutaneous adverse drug reactions in Han Chinese individuals: A pilot caseâ€“control study with both HLA gene and T cell receptor repertoire analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 133-143.	1.2	5
414	Pharmacogenomics in Clinical Care: Implications for Public Health. , 2020, , 111-130.		0
415	Association of carbamazepine-induced Stevensâ€“Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients. <i>Pharmacogenomics Journal</i> , 2020, 20, 533-541.	0.9	26
416	CD39+ regulatory T cells modulate the immune response to carbamazepine in HLA-B*15:02 carriers. <i>Immunobiology</i> , 2020, 225, 151868.	0.8	7
417	Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, populationâ€“based, cohort study in Taiwan. <i>Journal of Dermatology</i> , 2020, 47, 245-250.	0.6	17
418	Genetic variants associated with T cellâ€“mediated cutaneous adverse drug reactions: A PRISMAâ€“compliant systematic reviewâ€“An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1069-1098.	2.7	16
419	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, S16-S116.	2.0	107
420	Oxcarbazepine for Gambling Disorder. <i>American Journal of Therapeutics</i> , 2020, 27, e524-e525.	0.5	0
421	New era of personalised epilepsy management. <i>BMJ, The</i> , 2020, 371, m3658.	3.0	20
422	Genetic Testing in Epilepsy. <i>Seminars in Neurology</i> , 2020, 40, 730-738.	0.5	7
423	Precision medicine in drug safety. <i>Current Opinion in Toxicology</i> , 2020, 23-24, 87-97.	2.6	2
424	Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. <i>Frontiers in Pharmacology</i> , 2020, 11, 969.	1.6	38
425	Pharmacogenetic information in Swiss drug labels â€“ a systematic analysis. <i>Pharmacogenomics Journal</i> , 2021, 21, 423-434.	0.9	15
426	Genetic Influences on Disease Subtypes. <i>Annual Review of Genomics and Human Genetics</i> , 2020, 21, 413-435.	2.5	23
427	Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. <i>Human Immunology</i> , 2020, 81, 354-360.	1.2	13

#	ARTICLE	IF	CITATIONS
428	Utility evaluation of <i>HLA-B*13:01</i> screening in preventing trichloroethylene-induced hypersensitivity syndrome in a prospective cohort study. Occupational and Environmental Medicine, 2020, 77, 201-206.	1.3	8
429	Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care. Frontiers in Pharmacology, 2020, 11, 527.	1.6	16
430	An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 723-734.	1.5	12
431	Multidisciplinary care in Stevens-Johnson syndrome. Therapeutic Advances in Chronic Disease, 2020, 11, 204062231989446.	1.1	34
432	Pharmacogenomics in Precision Medicine. , 2020, , .		1
433	Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Review of Clinical Immunology, 2020, 16, 373-387.	1.3	20
434	Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis. Expert Opinion on Drug Safety, 2020, 19, 763-769.	1.0	3
435	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.0	41
436	Clinical usefulness of genetic testing for drug toxicity in cancer care: decision-makersâ€™ framing, knowledge and perceptions. New Genetics and Society, 2020, 39, 359-384.	0.7	0
437	Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clinics in Dermatology, 2020, 38, 607-612.	0.8	22
438	How Mechanism Knowledge Can Help to Management of Drug Hypersensitivity. Current Treatment Options in Allergy, 2020, 7, 14-31.	0.9	0
439	Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications. Clinical and Translational Science, 2020, 13, 861-870.	1.5	42
440	Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pacific Allergy, 2020, 10, e8.	0.6	15
441	A high-resolution HLA imputation system for the Taiwanese population: a study of the Taiwan Biobank. Pharmacogenomics Journal, 2020, 20, 695-704.	0.9	16
442	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Frontiers in Psychiatry, 2020, 11, 94.	1.3	74
443	The complexity of T cellâ€™mediated penicillin hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 150-167.	2.7	11
444	Global Frequencies of Clinically Important <i>HLA</i> Alleles and Their Implications For the Costâ€™Effectiveness of Preemptive Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2021, 109, 160-174.	2.3	35
445	Cutaneous Drug Reactions With Systemic Features. , 2021, , 743-752.e4.		0



#	ARTICLE	IF	CITATIONS
446	Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. Annual Review of Pharmacology and Toxicology, 2021, 61, 65-84.	4.2	26
447	The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 712-720.	1.3	8
448	Human Leukocyte Antigen Gene Testing and Carbamazepine-Induced Toxic Epidermal Necrolysis: A Study of Pediatric Practice. Journal of Cutaneous Medicine and Surgery, 2021, 25, 25-29.	0.6	4
449	An alarm system of carbamazepine-induced toxic effects highly associated with HLA-B*1502 allele. Kaohsiung Journal of Medical Sciences, 2021, 37, 156-157.	0.8	1
450	Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study. Clinical and Translational Science, 2021, 14, 1002-1014.	1.5	9
451	Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?. Current Treatment Options in Allergy, 2021, 8, 42-59.	0.9	0
452	Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 61-75.	0.4	7
453	Efficacy and tolerability of antiseizure drugs. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110374.	1.5	18
454	Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese. British Journal of Ophthalmology, 2022, 106, 610-615.	2.1	24
455	Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention. Frontiers in Genetics, 2020, 11, 607532.	1.1	3
456	The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity. Frontiers in Immunology, 2021, 12, 597761.	2.2	15
457	Toxic epidermal necrolysis (Lyell's syndrome) in a patient with HIV infection. Epidemiology and Infectious Diseases (Russian Journal), 2020, 25, 174-182.	0.1	0
458	Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention. Epilepsy and Behavior, 2021, 117, 107844.	0.9	4
459	Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Frontiers in Pharmacology, 2021, 12, 588063.	1.6	13
460	Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model. Pharmacogenomics Journal, 2021, 21, 476-483.	0.9	9
461	HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema. Frontiers in Pharmacology, 2021, 12, 671572.	1.6	8
462	Clinical Aspects of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications in Taiwan. Frontiers in Medicine, 2021, 8, 661891.	1.2	6
463	Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions. Journal of Personalized Medicine, 2021, 11, 383.	1.1	8

#	ARTICLE	IF	CITATIONS
464	The International Society of Pharmacovigilance (ISoP) Pharmacogenomic Special Interest Group: Pharmacogenomics in Pharmacovigilance. <i>Drug Safety</i> , 2021, 44, 615-617.	1.4	4
465	HLA-associated adverse drug reactions –scoping review. <i>Clinical and Translational Science</i> , 2021, 14, 1648-1658.	1.5	10
466	Visual Genomics Analysis Studio as a Tool to Analyze Multiomic Data. <i>Frontiers in Genetics</i> , 2021, 12, 642012.	1.1	14
467	Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-conscious Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 909-925.	2.3	19
468	Genetics of Severe Cutaneous Adverse Reactions. <i>Frontiers in Medicine</i> , 2021, 8, 652091.	1.2	11
469	Immunopharmacogenomics: Mechanisms of HLA-associated Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 607-615.	2.3	29
470	Turbidity Changes during Carbamazepine Oxidation by Photo-Fenton. <i>Catalysts</i> , 2021, 11, 894.	1.6	3
471	Technological readiness and implementation of genomic-driven precision medicine for complex diseases. <i>Journal of Internal Medicine</i> , 2021, 290, 602-620.	2.7	18
472	Molecular fingerprinting by single cell clone analysis in adverse drug reaction (ADR) assessment. <i>Current Drug Safety</i> , 2021, 16, .	0.3	0
473	Novel Pharmacogenomic Locus Implicated in Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. <i>Journal of the American College of Cardiology</i> , 2021, 78, 710-712.	1.2	2
474	Review of culprit drugs associated with patients admitted to the burn unit with the diagnosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Syndrome. <i>Burns</i> , 2022, 48, 1561-1573.	1.1	6
475	HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese. <i>International Journal of Dermatology</i> , 2021, , .	0.5	7
477	Cutaneous Adverse Drug Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2016, , 393-404.		1
478	Skin Diseases Caused by Factors from the Environment. , 2017, , 145-198.		3
479	Barriers and Solutions in Clinical Implementation of Pharmacogenomics for Personalized Medicine. , 2020, , 277-289.		5
480	Drug-Induced Liver Injury. , 2018, , 844-890.e17.		2
481	Seizures in Childhood. , 2011, , 2013-2039.e1.		34
482	Genome-wide Study Identifies Association between HLA-B*55:01 and Self-Reported Penicillin Allergy. <i>American Journal of Human Genetics</i> , 2020, 107, 612-621.	2.6	34

#	ARTICLE	IF	CITATIONS
484	The Epilepsy Prescriber's Guide to Antiepileptic Drugs. , 2013, , .		6
485	Carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in a Filipino with positive HLA-B75 serotype. BMJ Case Reports, 2018, 2018, bcr-2018-225028.	0.2	3
486	Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Research, 2020, 9, 612.	0.8	67
487	Severe cutaneous adverse reactions: impact of immunology, genetics, and pharmacology. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 17-27.	1.6	12
488	Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions. PLoS ONE, 2014, 9, e96990.	1.1	18
489	Pharmacogenetics of carbamazepine. Epilepsy and Paroxysmal Conditions, 2020, 11, 364-378.	0.2	3
490	HLA-B*58:01 is not the only risk factor associated with allopurinol-induced severe cutaneous adverse drug reactions. Annals of Translational Medicine, 2018, 6, S7-S7.	0.7	4
491	Gauging Reactive Metabolites in Drug-Induced Toxicity. Current Medicinal Chemistry, 2014, 22, 465-489.	1.2	10
492	An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3881-3901.	0.9	7
493	Early Biomarkers for Severe Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3829-3839.	0.9	8
494	Principles and Current Issues of Antiepileptic Drug Therapy. , 2013, , 149-229.		4
495	Pharmacogenomics Based Practice in Malaysia: The Attitude, Knowledge and Adoption by the Healthcare Professionals. IIUM Medical Journal Malaysia, 2014, 13, .	0.1	9
496	Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Dialogues in Clinical Neuroscience, 2016, 18, 313-322.	1.8	15
497	Genetic markers of severe cutaneous adverse reactions. Korean Journal of Internal Medicine, 2018, 33, 867-875.	0.7	25
498	Refining General Principles of Antiepileptic Drug Treatments for Epilepsy. Journal of Clinical		

#	ARTICLE	IF	CITATIONS
502	How Much Evidence is Necessary for Pharmacogenomic Testing Implementation?. Clinical & Experimental Pharmacology, 2012, 02, .	0.3	3
504	Pharmacogenomics in Developing Asian Countries. Advances in Microbial Ecology, 2012, , 183-214.	0.1	0
505	A Practitionerâ€™s Guide to Prescribing Carbamazepine for Adults with Intellectual Disabilities. , 2012, , 19-54.		0
506	Biomarkers associated with severe cutaneous adverse reactions. , 2012, , 431-439.		0
507	Pharmacogenetics and dermatology. , 2012, , 1-14.		0
509	Personalized Neurology. , 2013, , 575-612.		0
510	Exploratory Studies of Genetic Markers for Drug Adverse Reactions by GWAS Approaches. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 89-94.	0.1	0
512	Drug-Induced Liver Injury in Children: A Structured Approach to Diagnosis and Management. , 2014, , 371-388.		0
513	Systems biology approaches in asthma pharmacogenomics study. Allergy Asthma & Respiratory Disease, 2014, 2, 326.	0.3	1
514	Social Burden of Drug Allergy and its Prevention. Korean Journal of Medicine, 2014, 87, 647.	0.1	3
515	Emerging Molecular Applications and Summary. , 2014, , 341-354.		0
516	Severe Cutaneous Adverse Reaction. Korean Journal of Medicine, 2014, 87, 665.	0.1	4
518	Scientific Challenges and Implementation Barriers to Translation of Pharmacogenomics in Clinical Practice. , 2014, , 95-133.		1
520	Pathomechanism of SJS/TEN. Nishinohon Journal of Dermatology, 2015, 77, 337-339.	0.0	1
521	Prediction of Drug-Induced Adverse Reactions: Skin Hypersensitivity and Liver Toxicity. , 2015, , 47-61.		0
522	Pharmacogenetics of Adverse Drug Reactions. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 109-156.	0.6	0
523	TOXIC EPIDERMAL NECROLYSIS ( TEN / LYELL'S SYNDROME) IS A SERIOUS AND RAPIDLY PROGRESSIVE FATAL ERUPTION OF SKIN FOLLOWING CARBAMAZEPINE INTAKE, NEEDS PROMPT ADMISSION AND URGENT CARE. Journal of Evolution of Medical and Dental Sciences, 2015, 04, 1718-1722.	0.1	0
526	Methazolamide-induced toxic epidermal necrolysis confirmed by lymphocyte activation test. Allergy Asthma & Respiratory Disease, 2016, 4, 301.	0.3	0

#	ARTICLE	IF	CITATIONS
527	Concepts in Pharmacogenomics and Personalized Medicine. , 2016, , 1-32.		0
528	A life-threatening drug reaction. , 2016, , 227-240.		0
529	Personalized medicine in internal medicine. Klinicheskaia Meditsina, 2017, 95, 197-200.	0.2	0
531	Pharmacogenomics: A New Approach for Preventing Severe Cutaneous Adverse Drug Reactions. , 2018, , 373-409.		2
532	A Practical Approach to Demystifying Drug Allergy in the Intensive Care Unit. A Review Article. Open Journal of Internal Medicine, 2018, 08, 64-83.	0.1	0
533	Diagnostic utility of human leukocyte antigen B*15:02 screening in severe carbamazepine hypersensitivity syndrome. Annals of Indian Academy of Neurology, 2019, 22, 377.	0.2	6
534	Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?. Current Neuropharmacology, 2019, 17, 447-458.	1.4	2
536	An Update on the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions. Current Pharmaceutical Design, 2019, 25, 3813-3828.	0.9	2
537	HLA alleles associated with asparaginase hypersensitivity in Chinese children. Journal of Hematology and Oncology, 2021, 14, 182.	6.9	2
538	Analysis of trends and factors determining initial antiseizure medication choice for epilepsy in Taiwan. Seizure: the Journal of the British Epilepsy Association, 2021, 93, 145-153.	0.9	2
540	Drug Reactions. , 2020, , 695-756.		1
541	Analytical Challenges of Next-generation Sequencing in Precision Medicine. RSC Detection Science, 2020, , 153-168.	0.0	0
543	Ionizing irradiation protection and mitigation of murine cells by carbamazepine is p53 and autophagy independent. In Vivo, 2012, 26, 341-54.	0.6	3
545	Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations. Discovery Medicine, 2013, 16, 113-22.	0.5	19
546	NEW STRATEGIES TO PREDICT AND PREVENT SERIOUS IMMUNOLOGICALLY MEDIATED ADVERSE DRUG REACTIONS. Transactions of the American Clinical and Climatological Association, 2018, 129, 74-87.	0.9	5
548	Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders. , 2021, , .		0
549	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. Journal of Clinical Medicine, 2021, 10, 5317.	1.0	3
550	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in liver transplantation. Annals of Hepato-biliary-pancreatic Surgery, 2021, 25, 551-555.	0.1	1

#	ARTICLE	IF	CITATIONS
551	Secular Trends in the Incidence, Prevalence, and Medications for Epilepsy from 2007 to 2015 in Taiwan: A Nationwide Population-Based Study. <i>Neuroepidemiology</i> , 2021, 55, 484-494.	1.1	3
552	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. <i>Lancet Oncology</i> , The, 2022, 23, 172-184.	5.1	58
553	Unique motif shared by HLA-B*59:01 and HLA-B*55:02 is associated with methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 873-880.	1.3	8
554	The Immunogenetics of Cutaneous Drug Reactions. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1367, 411-431.	0.8	1
555	Risk Assessment in Drug Hypersensitivity: Detecting Small Molecules Which Outsmart the Immune System. <i>Frontiers in Allergy</i> , 2022, 3, 827893.	1.2	6
556	Incidence of Antiepileptic Medication-Induced Severe Cutaneous Adverse Reactions in Malaysia. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	2
557	Advances in the Pathomechanisms of Delayed Drug Hypersensitivity. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 357-373.	0.7	5
558	HLA-A*03 and response to immune checkpoint blockade in patients with cancer. <i>Lancet Oncology</i> , The, 2022, 23, e99.	5.1	0
559	Pharmacogenomics of Drug Hypersensitivity. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 335-355.	0.7	6
569	Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs. <i>Epileptic Disorders</i> , 2019, 21, 330-336.	0.7	0
570	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2022, 13, 886377.	1.6	14
571	Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics. <i>Journal of Human Genetics</i> , 2023, 68, 227-230.	1.1	2
572	Genetic markers for methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 764-764.	1.3	1
573	Carbamazepine-modified HLA-A*24:02-bound peptidome: Implication of CORO1A in skin rash. <i>International Immunopharmacology</i> , 2022, 109, 108804.	1.7	1
574	Cutaneous drug reactions with systemic features. , 2013, , 747-755.e2.		1
575	The Hypersensitivity Syndromes. , 2016, , 467-494.e6.		2
576	Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources. <i>Drug Safety</i> , 2022, 45, 511-519.	1.4	13
577	Clinical features and outcomes in children with <scp>Stevens-Johnson</scp> syndrome and toxic epidermal necrolysis. <i>Journal of Dermatology</i> , 2022, 49, 895-902.	0.6	5

#	ARTICLE	IF	CITATIONS
578	Genetic markers of drug hypersensitivity in pediatrics: current state and promise. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 715-728.	1.3	2
579	Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1039-1046.	1.0	1
580	Implementation of <i>NUDT15</i> Genotyping to Prevent Azathioprine-Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1079-1087.	2.3	5
581	Personalised future prescribing using pharmacogenomics: A resumé of a joint Royal College of Physicians / British Pharmacological Society working party report. <i>Future Healthcare Journal</i> , 2022, 9, 174-178.	0.6	4
582	Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
583	Awareness of <i>HLA-B*15:02</i> screening in trigeminal neuralgia and the gene screening policy among dentists in Southern Thailand. <i>Special Care in Dentistry</i> , 2023, 43, 286-293.	0.4	1
584	Drug allergy: 2022 practice parameter update. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1333-1393.	1.5	131
585	Pharmacogenetics of Cutaneous Adverse Drug Reactions. <i>Updates in Clinical Dermatology</i> , 2022, , 3-34.	0.1	0
586	Using human genetics to improve safety assessment of therapeutics. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 145-162.	21.5	20
587	Dentistry and Drug Adverse Events: Between Responsibilities and Regulations. <i>Toxics</i> , 2022, 10, 671.	1.6	0
588	Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 533-546.	0.7	3
589	Toxidermies. , 2022, , 71-76.		0
590	Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
591	A comparison of international treatment guidelines for <i>Stevens-Johnson Syndrome</i> and <i>Toxic Epidermal Necrolysis</i> . <i>International Journal of Dermatology</i> , 2023, 62, 397-403.	0.5	3
592	Chronic viral infection and toxic epidermal necrolysis (Lyell's syndrome). <i>Medical Alphabet</i> , 2022, 1, 15-18.	0.0	0
593	Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators. <i>Biomedicines</i> , 2023, 11, 177.	1.4	2
594	Predictive Strategies for ADRs – Biomarkers and <i>In Vitro</i> Models. , 2017, , 343-378.		0
595	A simple PCR-SSP method for detection of <i>HLA-B*15:02</i> , <i>*15:13</i> , and <i>*15:21</i> . <i>Biyokimya Dergisi</i> , 2023, .	0.1	0

#	ARTICLE	IF	CITATIONS
596	Therapeutisches Drug Monitoring und Bedside Genotyping. , 2022, , 219-250.		0
598	Current perspectives on the diagnosis and management of acute transverse myelitis. Expert Review of Neurotherapeutics, 2023, 23, 389-411.	1.4	2
599	La pharmacogÃ©nÃ©tique/pharmacogÃ©nomique en psychiatrie, perspectives thÃ©oriques et perspectives pour l'avenir. Information Psychiatrique, 2011, Volume 87, 697-703.	0.1	0
601	Black-Box Warnings of Antiseizure Medications: What is Inside the Box?. Pharmaceutical Medicine, 2023, 37, 233-250.	1.0	1
606	Genetic Contributions and Personalized Medicine. , 2023, , 3-17.		0
615	Pharmacogenetics: A New Approach for the Selection of the Right Drug. , 2023, , 77-98.		0